company background image
ALVIO logo

Valerio Therapeutics Société anonyme ENXTPA:ALVIO Stock Report

Last Price

€0.11

Market Cap

€16.8m

7D

9.2%

1Y

-64.2%

Updated

28 Mar, 2024

Data

Company Financials

Valerio Therapeutics Société anonyme

ENXTPA:ALVIO Stock Report

Market Cap: €16.8m

ALVIO Stock Overview

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide.

ALVIO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Valerio Therapeutics Société anonyme Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Valerio Therapeutics Société anonyme
Historical stock prices
Current Share Price€0.11
52 Week High€0.39
52 Week Low€0.09
Beta1.64
1 Month Change-9.17%
3 Month Change-33.94%
1 Year Change-64.20%
3 Year Change-84.88%
5 Year Change-86.54%
Change since IPO-99.18%

Recent News & Updates

Recent updates

Is Onxeo (EPA:ALONX) Weighed On By Its Debt Load?

Nov 16
Is Onxeo (EPA:ALONX) Weighed On By Its Debt Load?

Onxeo's (EPA:ALONX) Earnings Are Built On Soft Foundations

May 01
Onxeo's (EPA:ALONX) Earnings Are Built On Soft Foundations

Onxeo (EPA:ALONX) Share Prices Have Dropped 76% In The Last Five Years

Feb 12
Onxeo (EPA:ALONX) Share Prices Have Dropped 76% In The Last Five Years

How Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?

Dec 21
How Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?

Onxeo SA's (EPA:ONXEO) Profit Outlook

Nov 25
Onxeo SA's (EPA:ONXEO) Profit Outlook

Shareholder Returns

ALVIOFR BiotechsFR Market
7D9.2%1.0%0.4%
1Y-64.2%-1.8%9.6%

Return vs Industry: ALVIO underperformed the French Biotechs industry which returned -1.8% over the past year.

Return vs Market: ALVIO underperformed the French Market which returned 9.6% over the past year.

Price Volatility

Is ALVIO's price volatile compared to industry and market?
ALVIO volatility
ALVIO Average Weekly Movement8.3%
Biotechs Industry Average Movement5.8%
Market Average Movement4.2%
10% most volatile stocks in FR Market9.8%
10% least volatile stocks in FR Market2.2%

Stable Share Price: ALVIO's share price has been volatile over the past 3 months.

Volatility Over Time: ALVIO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
199739Shefali Agarwalhttps://valeriotx.com

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform.

Valerio Therapeutics Société anonyme Fundamentals Summary

How do Valerio Therapeutics Société anonyme's earnings and revenue compare to its market cap?
ALVIO fundamental statistics
Market cap€16.79m
Earnings (TTM)-€19.73m
Revenue (TTM)€1.44m

11.6x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALVIO income statement (TTM)
Revenue€1.44m
Cost of Revenue€491.00k
Gross Profit€952.00k
Other Expenses€20.69m
Earnings-€19.73m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin65.97%
Net Profit Margin-1,367.64%
Debt/Equity Ratio55.3%

How did ALVIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.